Inhibitory Effects of anti-Sp17 Monoclonal Antibody Against Human Ovarian Cancer Cell Line SKOV-3

Objective To investigate the inhibitory effect and mechanism of anti-Sp17 monoclonal antibody(mAb) on the growth of human ovarian cancer cells SKOV-3 in vitro. Methods Viability was assessed with the 3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide (MTT) assay after treatment with anti-Sp17 mAb.The ADCC and CDC activities of anti-Sp17 mAb were monitored using SKOV-3 cells as targets,healthy human peripheral blood monocytes and healthy human serum as effectors. Results Our preliminary results indicated that direct cytotoxicity of anti-Sp17 mAb against ovarian cancer cells was very low.However,the cytotoxic action of anti-Sp17 mAb mediated by PBMC,as ADCC,or mediated by human serum,as CDC,was noted in investigation of SKOV-3 cells. Conclusion anti-Sp17 mAb could provide a useful tool against ovarian cancer,and may provide insight into the development of low side-effect targeting therapy for this malignant disease.